Leap Therapeutics, Inc. (LPTX): Price and Financial Metrics


Leap Therapeutics, Inc. (LPTX): $1.32

0.11 (+9.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LPTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LPTX POWR Grades


  • Growth is the dimension where LPTX ranks best; there it ranks ahead of 65.46% of US stocks.
  • LPTX's strongest trending metric is Value; it's been moving down over the last 179 days.
  • LPTX ranks lowest in Momentum; there it ranks in the 4th percentile.

LPTX Stock Summary

  • For LPTX, its debt to operating expenses ratio is greater than that reported by merely 4.75% of US equities we're observing.
  • With a price/sales ratio of 105.98, Leap Therapeutics Inc has a higher such ratio than 97.7% of stocks in our set.
  • With a year-over-year growth in debt of -74.31%, Leap Therapeutics Inc's debt growth rate surpasses only 3.69% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Leap Therapeutics Inc, a group of peers worth examining would be CTMX, TMDI, SQZ, GLYC, and EIGR.
  • LPTX's SEC filings can be seen here. And to visit Leap Therapeutics Inc's official web site, go to www.leaptx.com.

LPTX Valuation Summary

  • In comparison to the median Healthcare stock, LPTX's price/sales ratio is 1700% higher, now standing at 68.4.
  • LPTX's EV/EBIT ratio has moved up 0.5 over the prior 56 months.
  • LPTX's price/earnings ratio has moved up 0.3 over the prior 56 months.

Below are key valuation metrics over time for LPTX.

Stock Date P/S P/B P/E EV/EBIT
LPTX 2021-08-31 68.4 3.4 -3.2 -2.0
LPTX 2021-08-30 68.2 3.4 -3.2 -2.0
LPTX 2021-08-27 69.6 3.5 -3.2 -2.1
LPTX 2021-08-26 69.2 3.5 -3.2 -2.1
LPTX 2021-08-25 71.2 3.6 -3.3 -2.2
LPTX 2021-08-24 72.4 3.6 -3.3 -2.2

LPTX Growth Metrics

    Its 2 year cash and equivalents growth rate is now at -24.98%.
  • The 5 year net cashflow from operations growth rate now stands at 5.43%.
  • The 5 year cash and equivalents growth rate now stands at 3246.66%.
LPTX's revenue has moved up $1,500,000 over the prior 61 months.

The table below shows LPTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1.5 -35.157 -40.587
2021-09-30 1.5 -30.429 -36.509
2021-06-30 1.5 -28.919 -32.427
2021-03-31 1.5 -30.618 -29.417
2020-12-31 1.5 -25.957 -37.588
2020-09-30 1.125 -25.863 -38.874

LPTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LPTX has a Quality Grade of D, ranking ahead of 18.21% of graded US stocks.
  • LPTX's asset turnover comes in at 0.03 -- ranking 351st of 682 Pharmaceutical Products stocks.
  • LNTH, ADMP, and CASI are the stocks whose asset turnover ratios are most correlated with LPTX.

The table below shows LPTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.030 1 5.490
2021-03-31 0.026 1 5.491
2020-12-31 0.028 1 5.014
2020-09-30 0.027 1 5.353
2020-06-30 0.025 1 5.974
2020-03-31 0.021 1 6.796

LPTX Price Target

For more insight on analysts targets of LPTX, see our LPTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.10 Average Broker Recommendation 1.4 (Strong Buy)

LPTX Stock Price Chart Interactive Chart >

Price chart for LPTX

LPTX Price/Volume Stats

Current price $1.32 52-week high $4.17
Prev. close $1.21 52-week low $0.92
Day low $1.15 Volume 1,327,900
Day high $1.40 Avg. volume 1,132,258
50-day MA $1.22 Dividend yield N/A
200-day MA $2.15 Market Cap 116.58M

Leap Therapeutics, Inc. (LPTX) Company Bio


Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in acquiring and developing therapeutics in cancer biology. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.


LPTX Latest News Stream


Event/Time News Detail
Loading, please wait...

LPTX Latest Social Stream


Loading social stream, please wait...

View Full LPTX Social Stream

Latest LPTX News From Around the Web

Below are the latest news stories about Leap Therapeutics Inc that investors may wish to consider to help them evaluate LPTX as an investment opportunity.

10 Cheap Pharmaceutical Stocks For 2022

In this article, we discuss 10 cheap pharmaceutical stocks for 2022. If you want to skip our detailed analysis of these stocks, go directly to 5 Cheap Pharmaceutical Stocks For 2022. The pharma industry is in the midst of a fundamental transformation as disruptive technologies like artificial intelligence, machine learning, and natural language processing become […]

Yahoo | February 15, 2022

How Many Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares Do Institutions Own?

Every investor in Leap Therapeutics, Inc. ( NASDAQ:LPTX ) should be aware of the most powerful shareholder groups...

Yahoo | February 8, 2022

Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ...

Investment company Act Capital Management, Llc (Current Portfolio) buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, AirSculpt Technologies Inc, enVVeno Medical Corp, sells , Upstart Holdings Inc, Affirm Holdings Inc, Nektar Therapeutics, Nuance Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Act Capital Management, Llc.

Yahoo | February 3, 2022

Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics (NASDAQ: LPTX), a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1 (DKK1). The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials.

Yahoo | January 31, 2022

Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, and Cynthia Sirard, MD, Chief Medical Officer, will present a corporate overview at the B. Riley Securities Oncology Investor Conference. The conference will be held in a virtual meeting format.

Yahoo | January 24, 2022

Read More 'LPTX' Stories Here

LPTX Price Returns

1-mo 18.92%
3-mo -24.14%
6-mo -58.88%
1-year -21.43%
3-year -26.26%
5-year -79.85%
YTD -59.26%
2021 44.00%
2020 100.89%
2019 -44.00%
2018 -67.95%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5011 seconds.